Contents

Search


off label use

use of a pharmaceutical agent for an indication not approved by the FDA. Indications: * 25% of antidepressant prescriptions in Canada for off-label use 2006-2015 [3] * of the off-label uses for antidepressants, only 3 with strong evidence supporting use [4] Epidemiology: - 12% of prescriptions for off-label use [2] Benefit/risk: - NNH = 1389 within 1 month [2] Adverse effects: - adverse events higher for off-label use FDA-approved use (19.7 vs. 12.5 per 10,000 person-months)

General

pharmacologic therapy

References

  1. Committee on Drugs Off-Label Use of Drugs in Children. Pediatrics. Feb 24, 2014 PMID: 24567009 http://pediatrics.aappublications.org/content/early/2014/02/18/peds.2013-4060.full.pdf
  2. Physician's First Watch, Nov 3, 2015 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org - Eguale T et al Association of Off-Label Drug Use and Adverse Drug Events in an Adult Population. JAMA Intern Med. Published online November 02, 2015 PMID: 26523731 http://archinte.jamanetwork.com/article.aspx?articleid=2467782 - Good CB, Gellad WF Off-Label Drug Use and Adverse Drug Events: Turning up the Heat on Off-Label Prescribing. JAMA Intern Med. Published online November 02, 2015 PMID: 26524668 http://archinte.jamanetwork.com/article.aspx?articleid=2467779
  3. Wong J et al Treatment Indications for Antidepressants Prescribed in Primary Care in Quebec, Canada, 2006-2015. JAMA. 2016;315(20):2230-2232 PMID: 27218634 http://jama.jamanetwork.com/article.aspx?articleid=2524175
  4. Wong J, Motulsky A, Abrahamowicz M et al. Off-label indications for antidepressants in primary care: Descriptive study of prescriptions from an indication based electronic prescribing system. BMJ 2017;356:j603 PMID: 28228380 Free PMC Article http://www.bmj.com/content/356/bmj.j603